BRITISH international development secretary Alok Sharma has pledged new UK aid to help build green cities across Africa with quality infrastructure.
Sharma, who is on a visit to Kenya, announced he would set up a UK Centre for Cities and Infrastructure, which will turbo-charge investment in fast growing cities across the developing world.
The centre will provide British expertise to African governments and city authorities to improve the way cities are planned, built and run, including making them more environmentally-friendly.
It will focus on improvements to infrastructure, including water and energy networks.
During his trip, Sharma also announced an expansion of the Department for International Development’s (DFID’s) Cities and Infrastructure for Growth programme to Ghana, Rwanda and Sierra Leone.
The programme helps UK businesses to invest in quality, resilient infrastructure, boosts access to reliable and affordable power and creates construction jobs.
Sharma’s trip came ahead of the UK-Africa Investment Summit next Monday (20), which will create new lasting partnerships to deliver more investment, jobs and growth, benefiting both Africa and the UK.
African cities produce more than half of the continent’s income, but too many suffer from poor connectivity and congestion, which continue to hinder growth.
The continent’s urban population is 472 million and set to double over the next 25 years. This growth provides an opportunity for African cities to prosper if the right infrastructure and jobs are available with the UK's support.
Last Sunday (12), Sharma visited Kisumu in western Kenya, where British businesses such as drinks company Diageo and solar power provider Azuri Technologies operate.
Diageo makes beer in its modern, environmentally-friendly brewery in the city, using sorghum plants from nearby farms. This in turn boosts the incomes of Kenyan farmers and helps them provide for their families.
Azuri, whose UK base is in Cambridge, provides pay-as-you go solar energy systems to off-grid homes across Africa, including in the Kisumu area.
This is helping families to store food in fridges and providing light for children to do their homework.
On Monday (13), the Asian-origin international business secretary opened the Securities Exchange in Nairobi. He was there for the listing of East Africa’s first green bond, which DFID helped Acorn Housing to develop, by providing British expertise.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.